SOAT1 and cancer: A large number of clinical trials related to JAK inhibitors are still in progress.326 With further understanding of the clinical potential of JAK inhibitors, their indications will also be expanded.327 For example, the combination of JAK inhibitors with PD-L1 monoclonal antibodies or inhibitors of relevant kinases such as STAT inhibitors in cancer treatment has a certain theoretical basis and data support.328 In addition, side effects should be considered in the clinical use of JAK inhibitors.